Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Xenetic Biosciences, Inc. (XBIO)

0.424   0.004 (0.98%) 03-24 11:01
Open: 0.42 Pre. Close: 0.4199
High: 0.424 Low: 0.42
Volume: 1,115 Market Cap: 6(M)

Technical analysis

as of: 2023-03-24 10:48:58 AM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 0.58     One year: 0.7
Support: Support1: 0.33    Support2: 0.27
Resistance: Resistance1: 0.49    Resistance2: 0.6
Pivot: 0.41
Moving Average: MA(5): 0.42     MA(20): 0.43
MA(100): 0.45     MA(250): 0.63
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 52.9     %D(3): 46
RSI: RSI(14): 43.1
52-week: High: 1.25  Low: 0.23
Average Vol(K): 3-Month: 62 (K)  10-Days: 36 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ XBIO ] has closed below upper band by 39.7%. Bollinger Bands are 36.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.42 - 0.42 0.42 - 0.42
Low: 0.4 - 0.41 0.41 - 0.41
Close: 0.42 - 0.42 0.42 - 0.42

Company Description

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Headline News

Mon, 20 Mar 2023
Febrile Neutropenia Market to Witness Growth by 2032, Estimates ... - Digital Journal

Thu, 16 Mar 2023
JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences - Yahoo Finance

Thu, 09 Feb 2023
Soligenix to implement 1-for-15 reverse stock split (NASDAQ:SNGX) - Seeking Alpha

Tue, 17 Jan 2023
Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy - Yahoo Finance

Thu, 01 Dec 2022
This Is Why Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Looks Appropriate - Yahoo Finance

Mon, 28 Nov 2022
KTRA stock jumps on FDA Fast Track status for breast cancer ... - Seeking Alpha

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 15 (M)
Shares Float 13 (M)
% Held by Insiders 13.8 (%)
% Held by Institutions 6.5 (%)
Shares Short 43 (K)
Shares Short P.Month 28 (K)

Stock Financials

EPS -1.71
EPS Est Next Qtl -0.26
EPS Est This Year -0.89
EPS Est Next Year -1.15
Book Value (p.s.) 1.39
Profit Margin (%) 0
Operating Margin (%) -452.8
Return on Assets (ttm) -23.9
Return on Equity (ttm) -39.9
Qtrly Rev. Growth 18.6
Gross Profit (p.s.) 0.07
Sales Per Share 0.1
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -5 (M)
Levered Free Cash Flow -4 (M)

Stock Valuations

PE Ratio -0.25
PEG Ratio 0
Price to Book value 0.3
Price to Sales 4.15
Price to Cash Flow -1.21

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-06-24
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.